Necrobiosis Lipodica (NL) Market Report 2026

The necrobiosis lipodica (nl) market size has grown strongly in recent years. It will grow from $4.35 billion in 2025 to $4.64 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising prevalence of diabetes-related skin disorders, increasing diagnosis through skin biopsy, reliance on corticosteroid-based therapies, limited availability of specialized dermatology care, slow adoption of advanced wound care products.

The necrobiosis lipodica (nl) market size is expected to see strong growth in the next few years. It will grow to $5.95 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to growing demand for biologics and immunomodulators, expansion of regenerative medicine solutions, increasing availability of laser and phototherapy devices, rising investment in dermatology clinical research, development of combination therapeutic protocols. Major trends in the forecast period include increasing use of phototherapy and laser-based modalities, rising adoption of advanced wound care and compression therapies, growing preference for topical and systemic immunomodulators, higher focus on early skin biopsy and differential diagnosis, expansion of regenerative medicine applications including stem cell therapy.

The increasing prevalence of diabetes is expected to propel the growth of the necrobiosis lipoidica (NL) market. Diabetes, a chronic condition in which the body struggles to regulate blood sugar due to insufficient insulin production or resistance, can lead to complications affecting the skin and other organs. Sedentary lifestyles, unhealthy diets, and genetic predisposition contribute to the rising number of diabetes cases, causing high blood sugar levels that damage small blood vessels (microangiopathy) and reduce oxygen and nutrient supply to the skin. This poor circulation makes the skin more vulnerable to injury, delayed healing, and the formation of yellowish, atrophic plaques characteristic of NL. For instance, in March 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, with the proportion achieving target HbA1c levels reaching 37.9%, the highest ever recorded by the National Diabetes Audit. Therefore, the rising prevalence of diabetes is driving the necrobiosis lipoidica market.

The growing incidence of autoimmune diseases is also expected to boost the necrobiosis lipoidica market. Autoimmune diseases occur when the body’s immune system mistakenly attacks its healthy tissues, leading to chronic inflammation and immune system dysfunction. These mechanisms contribute to NL by causing collagen degeneration and impairing skin healing. For instance, in September 2025, WeCovr, a UK-based insurance comparison platform, projected that over 3.5 million people in the United Kingdom would be living with an autoimmune disease. Therefore, the rising incidence of autoimmune disorders is fueling the growth of the NL market.

The increasing demand for personalized medicine is driving the necrobiosis lipoidica market. Personalized medicine focuses on tailoring healthcare based on diagnostic insights, molecular characteristics, and patient-specific clinical factors to optimize treatment safety and efficacy. NL’s heterogeneous presentation and variable response to therapies make it well-suited for precision-based approaches, emphasizing the need for individualized treatment plans. For instance, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the USFDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 approvals in 2022. Consequently, the growing focus on personalized medicine is further supporting the market growth for necrobiosis lipoidica.

Major companies operating in the necrobiosis lipodica (nl) market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co Inc, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Dr. Reddys Laboratories Ltd, Incyte Pharmaceuticals, Celltrion Healthcare Co Ltd, Almirall SA, Samsung Bioepis Co Ltd, HanAll Biopharma Co Ltd, AbbVie Inc, Amgen Inc, UCB Pharma SA, LEO Pharma AS, Bristol Myers Squibb Company, Roche Holding AG, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc.

North America was the largest region in the necrobiosis lipoidica market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrobiosis lipodica (nl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the necrobiosis lipodica (nl) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on dermatology devices, laser systems, and imported biologics have increased operational and treatment costs in the necrobiosis lipoidica market. Specialty clinics and hospitals that depend on imported phototherapy units and wound care technologies are most affected, especially in North America and Europe. These tariffs have slowed procurement cycles but encouraged local production, supporting long-term cost efficiency and supply stability.

The necrobiosis lipodica (nl) market research report is one of a series of new reports that provides necrobiosis lipodica (nl) market statistics, including necrobiosis lipodica (nl) industry global market size, regional shares, competitors with a necrobiosis lipodica (nl) market share, detailed necrobiosis lipodica (nl) market segments, market trends and opportunities, and any further data you may need to thrive in the necrobiosis lipodica (nl) industry. This necrobiosis lipodica (nl) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Necrobiosis lipoidica is a rare, chronic skin disorder characterized by yellowish, atrophic plaques with prominent blood vessels, most commonly appearing on the shins. The condition is associated with collagen degeneration, inflammation, and lipid accumulation in the skin.

The main treatment types for necrobiosis lipoidica (NL) include therapy, drugs, and other interventions. Therapy involves medical, psychological, or physical approaches aimed at relieving or healing the condition. Treatments can be administered via oral, topical, parenteral, and other routes. Diagnosis of NL typically involves methods such as skin biopsy, histopathology, and other diagnostic techniques. Treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and are used by end users including hospitals, home care services, specialty clinics, and other healthcare providers.

The necrobiosis lipoidica (NL) market consists of revenues earned by entities by provide services such as dermatology consultation, wound care services, and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The necrobiosis lipoidica market includes sales of corticosteroids, immunomodulators, corticosteroid creams, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.